本文来自微信公众号：凤凰网财经，作者：风暴眼 一场医疗机构违规风波，让头部眼科连锁品牌爱尔眼科被推上了舆论的风口浪尖。 2月3日，《新京报》发布调查报道，揭露襄阳、宜昌多地多家精神病医院存在多项违规行为：不仅违规收治正常人群、虚构诊疗项目，还高额 收取治疗费；甚至通过"假出院"的方式规避监管，或是刻意阻挠康复患者出院，将患者当作"创收工具"，大肆套取医保资金。 2月5日晚间，有媒体进一步指出，此次涉案的襄阳恒泰康医院，由爱尔医疗投资集团控股，实际控制人正是爱尔眼科的实控人陈邦。 爱尔眼科实控人陈邦图源网络 尽管爱尔眼科第一时间与涉事医院及其母公司做出切割，但凤凰网《风暴眼》发现，双方在人员和股权上确有交集。 而且与爱尔眼科股权有关联的公司中，此前至少有10家曾因分解收费、重复收费等行为造成医保基金损失，因此受到行政处罚。 更值得关注的是，由爱尔眼科大股东"爱尔医疗投资集团"实际控制的多家精神病医院，也同样因重复收费、过度诊疗、超标准收费造成医保基 金损失，被列入过处罚名单。 01 至少10家关联公司因医保基金违规而被处罚 2月6日，爱尔眼科发布了一则澄清公告，其中明确表示，此次卷入医保基金风波的襄阳恒泰康医院 ...

一场医疗机构违规风波，让头部眼科连锁品牌爱尔眼科被推上了舆论的风口浪尖。 来源丨凤凰网《风暴眼》 2月3日，《新京报》发布调查报道，揭露襄阳、宜昌多地多家精神病医院存在多项违规行为：不仅违规收治正常人群、虚构诊疗项目，还高额收取治 疗费；甚至通过"假出院"的方式规避监管，或是刻意阻挠康复患者出院，将患者当作"创收工具"，大肆套取医保资金。 2月5日晚间，有媒体进一步指出，此次涉案的襄阳恒泰康医院，由爱尔医疗投资集团控股，实际控制人正是爱尔眼科的实控人陈邦。 尽管爱尔眼科第一时间与涉事医院及其母公司做出切割，但凤凰网《风暴眼》发现，双方在人员和股权上确有交集。 而且与爱尔眼科股权有关联的公司中，此前至少有 10家曾因分解收费、重复收费等行为造成医保基金损失，因此受到行政处罚。 更值得关注的是，由爱尔眼科大股东 "爱尔医疗投资集团"实际控制的多家精神病医院，也同样因重复收费、过度诊疗、超标准收费造成医保基金损 失，被列入过处罚名单。 01 至少10家关联公司因医保基金违规而被处罚 2月6日，爱尔眼科发布了一则澄清公告，其中明确表示，此次卷入医保基金风波的襄阳恒泰康医院，并非爱尔眼科直接所属的医疗机构。 而这家机构 ...

文 | 《BUG》栏目 徐苑蕾 据媒体报道， 湖北多家精神病医院把正常人收进医院住院，医护人员利用住院信息虚构诊 疗项目，套取医保资金 ， 涉事医院包括襄阳融诚医院、襄阳宏安医院、襄阳恒泰康医院、 宜昌夷陵康宁精神病医院等。 其中襄阳恒泰康医院背后牵涉出 A股上市公司爱尔眼科 。 知名急诊医生艾芬率先在微博上 爆料，直指陈邦是襄阳恒泰康医院的实际控制人，这一爆料迅速引发市场哗然 。 根据天眼查资料， 襄阳恒泰康医院 有限公司 的 直接 股东为湖南恒泰康康复医疗产业发展 有限公司 （以下简称 "湖南恒泰康"），后者全资持股 ；而湖南恒泰 康 的间接控股股东则 是爱尔医疗投资集团有限公司 （以下简称 "爱尔医疗投资"），爱尔医疗投资同时也是爱尔 眼科的第一大股东，持股比例为3 4.34% 。 湖北多家精神病医院被曝虚构诊疗项目、违规收治正常人以套取医保资金的事件持续发酵 ， 其中襄阳恒泰康医院背后浮现爱尔眼科实际控制人陈邦的身影，将这家民营眼科 头部企 业 推向舆论风口。 爱尔眼科紧急发布声明，试图划清与涉事医院的边界 。 爱尔眼科方面称，襄阳恒泰康医院 有限公司并非爱尔眼科上市公司体系内企业。该公司为爱尔医疗投 ...

来源：南财社 湖北的精神病医院骗保，竟然和上市公司的实控人扯上了关系。 近日，新京报报道湖北襄阳、宜昌多家精神病院被曝以"免费住院""免费接送"为诱导招揽病人，涉嫌系 统性骗取医保资金，引起广泛关注。 而智通财经又通过公开资料对比发现，被报道点名的襄阳恒泰康医院在股权穿透后，实际控制人为A股 上市公司爱尔眼科实际控制人陈邦。 公开信息显示，陈邦，1965年9月出生，湖南长沙人，研究生学历，湖南大学兼职MBA导师、爱尔眼科 创始人，历任长沙爱尔眼科医院副董事长、长沙爱尔眼科医院集团副董事长、爱尔眼科医院集团董事 长。现任湖南爱尔投资董事长兼总经理、爱尔眼科董事长。 消息一出，昨日多家媒体致电爱尔眼科医院集团股份有限公司董事长陈邦、副董事长李力，均无果。还 有记者联系到了爱尔眼科的董秘吴士君，被对方以"信号不好""正在办登机"为由，挂断了电话。 01 爱尔医疗被卷入"骗保门" 旗下多家精神病院涉及骗保 据天眼查网站，襄阳恒泰康医院成立于2019年，为爱尔医疗集团旗下成员，企业注册资本500万元，实 缴资本500万元，控股股东为湖南恒泰康康复医疗产业发展有限公司。 值得注意的是，湖南恒泰康康复医疗产业发展有限公司与 ...

Core Viewpoint - The article highlights the practice of marketing sunscreen products as "medical isolation pads" to exploit insurance reimbursement opportunities, revealing a trend in the pharmaceutical retail industry that blurs the lines between medical and non-medical products [1]. Group 1: Product Mislabeling - A sunscreen ice sleeve is marketed as a "medical isolation pad" to enable insurance reimbursement [1]. - The product's labeling as "medical" allows it to be sold in pharmacies and processed through health insurance, despite being a non-medical item [1]. Group 2: Market Strategy - The manufacturer, Henan Chaoya New Materials Co., has leveraged the "medical-grade" label to capture a larger market share and increase profits [1]. - The company has partnered with a leading pharmacy chain, resulting in an order worth 90 million yuan (approximately 13 million USD) for sunscreen masks and sleeves distributed to nearly 20,000 pharmacies nationwide [1]. Group 3: Regulatory Environment - "Medical isolation pads" are classified as Class I medical devices, which have lower risks and simpler registration processes, allowing non-medical products to meet compliance requirements [1]. - These products are assigned a unique 27-digit medical insurance code, enabling them to qualify for insurance reimbursement in certain regions [1].

Core Viewpoint - The Inner Mongolia Hohhot Medical Security Bureau has reported violations by Inner Mongolia Renhe Tang Pharmaceutical Chain Co., Ltd., leading to the termination of medical insurance agreements and recovery of related illegal fees due to the exchange of daily necessities for drug settlements [1][3]. Group 1: Violation Details - Two branches of Inner Mongolia Renhe Tang Pharmaceutical Chain Co., Ltd. were found to have engaged in the practice of exchanging daily necessities for drug settlements, resulting in the termination of their medical insurance agreements and the recovery of illegal fees [1][3]. - The medical security bureau acted on complaints from the public and conducted investigations, confirming the violations at the 161st and 162nd branches of the company [3]. - The company has a history of violations, with previous branches (157th and 158th) reported for similar issues last year, leading to the termination of their medical insurance agreements and a one-year ban on applying for medical insurance designation [3]. Group 2: Company Background - Inner Mongolia Renhe Tang Pharmaceutical Chain Co., Ltd. was established in 2003 and is a national pharmaceutical chain with nearly 1,500 direct stores [4][5]. - The company is primarily owned by Linyi Renhe Tang Pharmaceutical (Chain) Co., Ltd., which holds 85.44% of the shares, and is ultimately controlled by Xiangyu Industrial Group Co., Ltd. [4]. - The company has been recognized for six consecutive years as one of the "Top 100 Direct Chain Pharmacies in China" and "Top 100 Comprehensive Competitiveness Chain Pharmacies in China" [5].

Core Viewpoint - The company, Shuyupingmin, is facing a severe crisis marked by a significant loss in its first annual report since going public, the termination of medical insurance agreements, and a notable share sell-off by its founder, raising concerns about its future viability and investor confidence [1][10]. Group 1: Company Performance and Financials - Shuyupingmin reported its first annual loss since its IPO, with a staggering quarterly loss of 176 million yuan, a year-on-year decline of 509.43% [6]. - The company's gross margin has dropped to 27.27%, which is 6 percentage points lower than the industry average, indicating a structural decline in the sales of core products [6]. - The total number of stores decreased by 118 in the past year, with new store openings slowing down to 1,698, a 9.73% reduction from the previous year [6]. - The company's asset-liability ratio surged to 77.16%, with current liabilities reaching 5.595 billion yuan, signaling a critical cash flow situation [7]. Group 2: Regulatory Issues and Market Reactions - The company has faced multiple terminations of medical insurance agreements due to violations, with at least 22 stores in Qingdao losing their insurance qualification this year alone [5]. - A major scandal involving fraudulent insurance claims at one of its stores led to the complete termination of its insurance agreements and criminal investigations, further damaging its reputation [5]. - The founder's decision to sell 3% of her shares for approximately 150 million yuan amid these crises has been interpreted as a lack of confidence in the company's future [10]. - The market has reacted negatively to the company's performance and regulatory issues, with significant share sell-offs from major stakeholders, including Alibaba Health, which sold 4.64 million shares [10].